Home » Stocks » CWBR

CohBar, Inc. (CWBR)

Stock Price: $1.13 USD -0.01 (-0.88%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $1.11 -0.02 (-1.77%) Apr 16, 4:04 PM
Market Cap 69.82M
Revenue (ttm) n/a
Net Income (ttm) -16.26M
Shares Out 61.12M
EPS (ttm) -0.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $1.13
Previous Close $1.14
Change ($) -0.01
Change (%) -0.88%
Day's Open 1.19
Day's Range 1.12 - 1.19
Day's Volume 428,643
52-Week Range 0.85 - 4.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

2 weeks ago - GlobeNewsWire

MENLO PARK, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...

2 weeks ago - GlobeNewsWire

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

1 month ago - GlobeNewsWire

MENLO PARK, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...

1 month ago - GlobeNewsWire

MENLO PARK, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...

1 month ago - GlobeNewsWire

MENLO PARK, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

2 months ago - GlobeNewsWire

MENLO PARK, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

2 months ago - GlobeNewsWire

MENLO PARK, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

4 months ago - GlobeNewsWire

MENLO PARK, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

4 months ago - GlobeNewsWire

CohBar, Inc. (CWBR) CEO Steve Engle on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

5 months ago - GlobeNewsWire

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

5 months ago - GlobeNewsWire

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Other stocks mentioned: CI, DRRX, GRFS, PTI
5 months ago - Zacks Investment Research

MENLO PARK, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

5 months ago - GlobeNewsWire

MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

5 months ago - GlobeNewsWire

Company to host a Key Opinion Leader webinar on the current treatment landscape in IPF, the unmet need, and positive findings from preclinical studies of CohBar's CB5138 Analogs on Friday, November 6 at...

5 months ago - GlobeNewsWire

MENLO PARK, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

6 months ago - GlobeNewsWire

MENLO PARK, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

6 months ago - GlobeNewsWire

MENLO PARK, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

6 months ago - GlobeNewsWire

MENLO PARK, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exte...

6 months ago - GlobeNewsWire

MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exte...

7 months ago - GlobeNewsWire

MENLO PARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exte...

7 months ago - GlobeNewsWire

MENLO PARK, Calif., Aug. 28, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic di...

7 months ago - GlobeNewsWire

MENLO PARK, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic di...

7 months ago - GlobeNewsWire

MENLO PARK, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic di...

7 months ago - GlobeNewsWire

MENLO PARK, Calif., Aug. 24, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten...

7 months ago - GlobeNewsWire

CohBar, Inc. (CWBR) CEO Steve Engle on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

New positive preliminary preclinical results in ARDS model Company to host conference call and webcast at 5:00 p.m. ET

8 months ago - GlobeNewsWire

In vivo data demonstrates antifibrotic effects of multiple novel peptide analogs in preclinical models of idiopathic pulmonary fibrosis (IPF) In vivo data demonstrates antifibrotic effects of multiple n...

8 months ago - GlobeNewsWire

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

8 months ago - GlobeNewsWire

MENLO PARK, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten...

9 months ago - GlobeNewsWire

MENLO PARK, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten...

9 months ago - GlobeNewsWire

MENLO PARK, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten...

9 months ago - GlobeNewsWire

MENLO PARK, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...

10 months ago - GlobeNewsWire

CohBar, Inc. (CWBR) CEO Steve Engle on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Former senior executive to continue on CohBar Board of Directors Former senior executive to continue on CohBar Board of Directors

11 months ago - GlobeNewsWire

CohBar Looks Undervalued Ahead Of Upcoming Data Readout

11 months ago - Seeking Alpha

Preclinical Testing of CB5064 Analogs Initiated in ARDS Preclinical Testing of CB5064 Analogs Initiated in ARDS

11 months ago - GlobeNewsWire

MENLO PARK, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...

11 months ago - GlobeNewsWire

COVID-19 Pandemic Impact at Clinical Sites Delays Study COVID-19 Pandemic Impact at Clinical Sites Delays Study

1 year ago - GlobeNewsWire

CohBar's (CWBR) CEO Steve Engle on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Anti-tumor effects demonstrated in vivo in preclinical melanoma immuno-oncology model Anti-tumor effects demonstrated in vivo in preclinical melanoma immuno-oncology model

1 year ago - GlobeNewsWire

New results also confirm anti-inflammatory effect New results also confirm anti-inflammatory effect

1 year ago - GlobeNewsWire

CohBar's (CWBR) CEO Steve Engle on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

CohBar - The Pioneer In Mitochondrial Drugs

1 year ago - Seeking Alpha

MENLO PARK, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and e...

1 year ago - GlobeNewsWire

MENLO PARK, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and e...

1 year ago - GlobeNewsWire

MENLO PARK, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and ...

1 year ago - GlobeNewsWire

CohBar, Inc. (CWBR) CEO Steven Engle on Q2 2019 - Earnings Call Transcript

1 year ago - Seeking Alpha

CohBar Inc. (CWBR) Interim CEO Philippe Calais on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About CWBR

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of ... [Read more...]

Industry
Biotechnology
Founded
2007
Stock Exchange
NASDAQ
Ticker Symbol
CWBR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CohBar stock is "Strong Buy." The 12-month stock price forecast is 6.40, which is an increase of 466.37% from the latest price.

Price Target
$6.40
(466.37% upside)
Analyst Consensus: Strong Buy